Effects of photodynamic therapy on rapidly growing nontuberculous mycobacteria keratitis

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 1, 2011, Pages 223-229

  Shin, Min Hsiu ^a   Huang, Fu Chin ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CIPROFLOXACIN; METHYLENE BLUE; MOXIFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; BACTERIUM ISOLATE; BROTH DILUTION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KERATITIS; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM FORTUITUM KERATITIS; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; RABBIT; THERAPY EFFECT; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; ATYPICAL MYCOBACTERIOSIS; BACTERIAL EYE INFECTION; CORNEA ULCER; DRUG POTENTIATION; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PHOTOCHEMOTHERAPY;

AMIKACIN; ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; CORNEAL ULCER; DRUG SYNERGISM; EYE INFECTIONS, BACTERIAL; METHYLENE BLUE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS, ATYPICAL; PHOTOCHEMOTHERAPY; QUINOLINES; RABBITS;

EID: 79952203223     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5593     Document Type: Article

References (29)

1. Tseng SH, Hsiao WC. Therapeutic lamellar keratectomy in the management of nontuberculous mycobacterium keratitis refractory to medical treatments. Cornea. 1995;14:161-166.
2. Reviglio V, Rodriguez ML, Picotti GS, et al. Mycobacterium chelo-nae keratitis following laser in situ keratomileusis. J Refract Surg. 1998;14:357-360.
3. Wallace RJ, Swenson JM, Silcox VA, Good RC, Tschen JA, Stone MS. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis. 1983;5:657-679.
4. Brown-Elliott BA, Wallace RJ, Crist CJ, et al. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother. 2002;46:3283-3285.
5. Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother. 2003;47:1958-1962.
6. O'Riordan K, Sharlin DS, Gross J, et al. Photoinactivation of myco-bacteria in vitro and in a new murine model of localized Mycobac-terium bovis BCG-induced granulomatous infection. Antimicrob Agents Chemother. 2006;50:1828-1834.
7. Wiegell SR, Kongshoj B, Wulf HC. Mycobacterium marinum infection cured by photodynamic therapy. Arch Dermatol. 2006; 142:1241-1242.
8. Jori G, Fabris C, Soncin M, et al. Photodynamic therapy in the treatment of microbial infections: basic principles and perspective applications. Lasers Surg Med. 2006;38:468-481.
9. O'Riordan K, Akilov OE, Hasan T. The potential for photodynamic therapy in the treatment of localized infections. Photodiagn Pho-todyn Ther. 2005;2:247-262.
10. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother. 1998;42:13-28.
11. Schultz EW, Krueger AP. Inactivation of staphylococcus bacterio-phage by methylene blue. Proc Soc Exp Biol Med. 1928;26:100- 101.
12. Demidova TN, Hamblin MR. Photodynamic inactivation of Bacillus spores mediated by phenothiazinium dyes. Appl Environ Micro-biol. 2005;71:6918-6925.
13. Harris F, Chatfield LK, Phoenix DA. Phenothiazinium based pho-tosensitizers-photodynamic agents with a multiplicity of cellular targets and clinical applications. Curr Drugs Targets. 2005;6: 615- 627.
14. Menezes S, Capella MA, Caldas LR. Photodynamic action of meth-ylene blue: repair and mutation in Escherichia coli. J Photochem Photobiol B. 1990;5:505-517.
15. Phoenix DA, Sayed Z, Hussain S, et al. The phototoxicity of phe-nothiazinium derivatives against Escherichia coli and Staphylococ-cus aureus. FEMS Immunol Med Microbiol. 2003;39:17-22.
16. Soukos NS, Wilson M, Burns T, et al. Photodynamic effects of toluidine blue on human oral keratinocytes and fibroblasts and Streptococcus sanguis evaluated in vitro. Lasers Surg Med. 1996; 18:253-259.
17. Teichert MC, Jones JW, Usacheva MN, et al. Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model. Oral Surg Oral Med Oral Radiol Endod. 2002;93:155-160.
18. Wilson M, Mia N. Effect of environmental factors on the lethal photosensitization of Candida albicans in vitro. Lasers Med Sci. 1994;9:105-109.
19. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardia, and Other AerobicActinomycetes: Tentative Standards. 2nd ed. M24- T2. Wayne, PA: NCCLS; 2002.
20. Ren M, Wu X. Evaluation of three different methods to establish animal models of Acanthamoeba keratitis. Yonsei Med J. 2010; 51:121-127.
21. Tang HM, Hamblin MR, Yow CM. A comparative in vitro photoin-activation study of clinical isolates of multidrug-resistant pathogens. J Infect Chemother. 2007;13:87-91.
22. Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease. Photochem Photobiol Sci. 2004;3: 436-450.
23. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004; 5:497-508.
24. Wainwright M, Giddens RM. Phenothiazinium photosensitisers: choices in synthesis and application. Dyes Pigments. 2003;57: 245- 257.
25. Phoenix DA, Harris F. Phenothiazinium-based photosensitizers: antibacterials of the future. Trends Mol Med. 2003;9:283-285.
26. Tegos GP, Hamblin MR. Phenothiazinium antimicrobial photosen-sitizers are substrates of bacterial multidrug resistance pumps. Antimicrob Agents Chemother. 2006;50:196-203.
27. Chen Z, Xuguang S, Zhiqun W, et al. In vitro amoebacidal activity of photodynamic therapy on Acanthamoeba. Br J Ophthalmol. 2008;92:1283-1286.
28. O'Brien TP, Matoba AY. Nontuberculous mycobacterial diseases. In: Pepose JS, Holland GN, Wilhemus KR, eds.Ocular Infection and Immunity. St Louis, MO: Mosby-Year Book Inc.; 1996:1033- 1041.
29. Eiferman RA, Stagner JI. Intraocular penetration of amikacin: iris binding and bioavailability. Arch Ophthalmol. 1982;100:1817-1819.